Declining profitability due to drug pricing regulations and healthcare system reforms
First written in FY2023. 2 of 3 entries say "Restated". Latest entry: FY2025.
The whole theme swung hardest in 2018: 20 of 65 companies on the "Worse" side.
47 other companies' latest entry also says "Restated".
- FY2025RestatedAnnual report
「The prices of our pharmaceuticals and regenerative medicine products that we seek to commercialize may be lower than expected, which may affect our business performance and financial position.」
The company reiterates the risk that drug-price regulation and healthcare-system reform may reduce expected prices and earnings. - FY2024RestatedAnnual report
「The prices of our pharmaceuticals and regenerative medicine products that we seek to commercialize may be lower than expected, which may affect our business performance and financial position.」
The company reiterates the risk that drug-price revisions and healthcare-cost containment measures may reduce expected prices and earnings. - FY2023First statedAnnual report
「The prices of our pharmaceuticals and regenerative medicine products that we seek to commercialize may be lower than expected, which may affect our business performance and financial position.」
The company indicates that drug-price revisions and healthcare-cost containment measures in various countries may result in lower-than-expected prices and earnings.